ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s pipeline of therapies designed to counter resistance mechanisms in cancer within the following areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Co.'s primary product candidate is ORIC-101, a selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. Co.'s other product candidates include: ORIC-533, a small molecule inhibitor of CD73; ORIC-944, an allosteric inhibitor of PRC2 via the EED subunit; and ORIC-114, a brain penetrant irreversible inhibitor. The ORIC stock yearly return is shown above.
The yearly return on the ORIC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ORIC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|